azalanstat has been researched along with 1-(4-(3-bromophenoxy)butyl)-1h-imidazole in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Acquaviva, R; Barbagallo, I; Di Giacomo, C; Modica, MN; Pittalà, V; Romeo, G; Salerno, L; Siracusa, MA; Sorrenti, V; Tibullo, D | 1 |
| Amata, E; Barbagallo, I; Di Raimondo, F; Dichiara, M; Floresta, G; Intagliata, S; Marrazzo, A; Pittalà, V; Prezzavento, O; Rescifina, A; Romeo, G; Salerno, L; Sorrenti, V; Tibullo, D; Turnaturi, R; Vanella, L | 1 |
2 other study(ies) available for azalanstat and 1-(4-(3-bromophenoxy)butyl)-1h-imidazole
| Article | Year |
|---|---|
Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.
Topics: Animals; Antineoplastic Agents; Brain; Cell Cycle Checkpoints; Cell Line; Cell Survival; Enzyme Inhibitors; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Humans; Imidazoles; Male; Rats; Rats, Sprague-Dawley; RNA, Messenger; Spleen; Triazoles | 2013 |
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
Topics: Antineoplastic Agents; Cell Survival; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Heme Oxygenase-1; Humans; Imatinib Mesylate; Imidazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation | 2018 |